U. Landmesser Et Al. , "European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk," EUROPEAN HEART JOURNAL , vol.38, no.29, pp.2245-2255, 2017
Landmesser, U. Et Al. 2017. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. EUROPEAN HEART JOURNAL , vol.38, no.29 , 2245-2255.
Landmesser, U., Chapman, M. J., Farnier, M., Gencer, B., Gielen, S., Hovingh, G. K., ... Luscher, T. F.(2017). European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. EUROPEAN HEART JOURNAL , vol.38, no.29, 2245-2255.
Landmesser, Ulf Et Al. "European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk," EUROPEAN HEART JOURNAL , vol.38, no.29, 2245-2255, 2017
Landmesser, Ulf Et Al. "European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk." EUROPEAN HEART JOURNAL , vol.38, no.29, pp.2245-2255, 2017
Landmesser, U. Et Al. (2017) . "European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk." EUROPEAN HEART JOURNAL , vol.38, no.29, pp.2245-2255.
@article{article, author={Ulf Landmesser Et Al. }, title={European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk}, journal={EUROPEAN HEART JOURNAL}, year=2017, pages={2245-2255} }